Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Top Cited Papers
Open Access
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Infection
- Vol. 81 (1), E1-E5
- https://doi.org/10.1016/j.jinf.2020.03.002
Abstract
No abstract availableKeywords
Funding Information
- Sun Yat-sen University
This publication has 22 references indexed in Scilit:
- A review of treatment modalities for Middle East Respiratory SyndromeJournal of Antimicrobial Chemotherapy, 2016
- Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort studyThe Lancet Infectious Diseases, 2014
- Arbidol as a broad-spectrum antiviral: An updateAntiviral Research, 2014
- Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapyFuture Virology, 2011
- Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyThe Lancet, 2008
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003
- Lopinavir/RitonavirDrugs, 2003
- Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzymeFEBS Letters, 2002